U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H7NO.H3O4P
Molecular Weight 243.1532
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYQUINOLINE PHOSPHATE

SMILES

OP(O)(O)=O.OC1=CC=CC2=C1N=CC=C2

InChI

InChIKey=QTLGWYAJVCWZFL-UHFFFAOYSA-N
InChI=1S/C9H7NO.H3O4P/c11-8-5-1-3-7-4-2-6-10-9(7)8;1-5(2,3)4/h1-6,11H;(H3,1,2,3,4)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.cosmeticsinfo.org/ingredient/benzoxiquine-0

In cosmetics and personal care products, Benzoxiquine has been reported to be used in the formulation of hair tonics, dressings, and other hair grooming aids. Benzoxiquine is described as a biocide for use in cosmetic products. It is currently reported to be used in only one product. In a separate finding, the Food and Drug Administration determined that Benzoxiquine is not generally recognized as safe and effective in over-the-counter topical antifungal drug products. The only data available on the toxicity of Benzoxiquine indicates that it is mutagenic in the Ames test without metabolic activation. Because of the lack of data, the safety of Benzoxiquine could not be substantiated. The data needed to make a safety assessment include purity/impurities, ultraviolet absorption (if there is absorption, then photosensitization data will be needed), 28-day dermal toxicity, dermal teratogenicity, ocular irritation (if already available only), dermal irritation and sensitization, and two different genotoxicity studies (one using a mammalian system). If the latter data are positive, dermal carcinogenesis data using the methods of the National Toxicology Program will be needed. It cannot be concluded that Benzoxiquine is safe for use in cosmetic products until these safety data have been obtained and evaluated.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
In vitro studies of the antibacterial and antifungal activity of oxine and its derivatives.
1994 Aug
Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction.
2013 Mar 28
Patents

Patents

Sample Use Guides

Unknown
Route of Administration: Topical
In Vitro Use Guide
Unknown
Name Type Language
OXYQUINOLINE PHOSPHATE
Common Name English
8-QUINOLINOL, PHOSPHATE (1:1) (SALT)
Systematic Name English
IPO-3779
Code English
Code System Code Type Description
PUBCHEM
3015104
Created by admin on Fri Dec 15 17:55:25 GMT 2023 , Edited by admin on Fri Dec 15 17:55:25 GMT 2023
PRIMARY
FDA UNII
4HLV5M1632
Created by admin on Fri Dec 15 17:55:25 GMT 2023 , Edited by admin on Fri Dec 15 17:55:25 GMT 2023
PRIMARY
CAS
21288-28-8
Created by admin on Fri Dec 15 17:55:25 GMT 2023 , Edited by admin on Fri Dec 15 17:55:25 GMT 2023
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID7066695
Created by admin on Fri Dec 15 17:55:25 GMT 2023 , Edited by admin on Fri Dec 15 17:55:25 GMT 2023
PRIMARY
CAS
63716-67-6
Created by admin on Fri Dec 15 17:55:25 GMT 2023 , Edited by admin on Fri Dec 15 17:55:25 GMT 2023
PRIMARY